Intravenous Allopurinol in Heart Failure

Completed · Phase 2 · Has a placebo group

Conditions studied: Congestive Heart Failure

In brief

This study tests the hypothesis that allopurinol, a xanthine oxidase inhibitor, improves heart metabolism in patients with heart failure.

Key facts

Study ID

NCT00181155

Run by

Johns Hopkins University

People needed

18

Starts

2004-11-01

Expected to finish

2010-12-01

Last updated by the study team

2017-05-30

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age > 18 years
• The patient is willing and able to provide informed consent
• Clinical diagnosis of chronic heart failure
• Ejection fraction (EF) < 40% by echocardiography, nuclear multigated acquisition (MUGA) or cath ventriculography
• No significant coronary disease at cardiac catheterization
• New York Heart Association (NYHA) Class I-IV symptoms
• Clinical stabilization for two weeks if following recent congestive heart failure (CHF) decompensation.

You may not qualify if…

• Metallic implant prohibiting magnetic resonance (MR) evaluation
• Inability to lie flat for MR study
• Administration of additional investigational drugs
• Calculated creatinine clearance < 50 mL/min
• Allergy to allopurinol
• Current gout flare
• Currently taking oral allopurinol

Where it is running

• Johns Hopkins Hospital — Baltimore, Maryland, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.